Clinical Trials Browser

INDUSTRY × Breast Neoplasms × capivasertib × Clear all

Breast Neoplasms

NCT06982521 2026-04-02

ReDiscover-2

Phase 3 Recruiting

540 enrolled

Breast

Breast Neoplasms

NCT06635447 2026-03-27

CAPItrue

Phase 3 Active not recruiting

258 enrolled

Breast

Breast Neoplasms, Disease Progression

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Recruiting

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

396 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

923 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Phase 1 Completed

285 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Clinical Trials

CAPItana

ReDiscover-2

CAPItrue

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

BEGONIA

SERENA-1

ELEVATE

CAPItello-290

DB-08

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules